MABLINK BIOSCIENCE
Mablink Bioscience is a biotechnology company specialized in the development of a new class of cancer drugs, called Antibody Drug Conjugate (ADC).
MABLINK BIOSCIENCE
Industry:
Biotechnology Pharmaceutical
Founded:
2018-01-01
Address:
Lyon, Rhone-Alpes, France
Country:
France
Website Url:
http://www.mablink.com
Total Employee:
1+
Status:
Active
Total Funding:
4 M EUR
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress
Similar Organizations
Faze Medicines
Faze Medicines is a biotechnology company.
ImmunOs Therapeutics
ImmunOs Therapeutics is a clinical-stage biotechnology company.
Magpie Pharmaceuticals
Magpie Pharmaceuticals is a biotechnology company.
Themis Bioscience
Themis Bioscience is a start-up biotechnology company.
Current Advisors List
Board_member
Current Employees Featured
Jean-Guillaume Lafay Chief Executive Officer & Co-Founder @ Mablink Bioscience
Chief Executive Officer & Co-Founder
2018-01-01
Frédérique Brune Chief Development Officer @ Mablink Bioscience
Chief Development Officer
2022-02-01
Warren Viricel CSO and Co-Founder @ Mablink Bioscience
CSO and Co-Founder
2018-12-01
Founder
Investors List
Pertinence Invest
Pertinence Invest investment in Seed Round - Mablink Bioscience
Elaia
Elaia investment in Seed Round - Mablink Bioscience
Simba Santé
Simba Santé investment in Seed Round - Mablink Bioscience
Fournier-Majoie
Fournier-Majoie investment in Seed Round - Mablink Bioscience
Crédit Agricole
Crédit Agricole investment in Seed Round - Mablink Bioscience
Sham Innovation Santé
Sham Innovation Santé investment in Seed Round - Mablink Bioscience
Key Employee Changes
| Date | New article |
|---|---|
| 2022-03-01 | Mablink Bioscience announces appointment of its Chief Development Officer |
Official Site Inspections
http://www.mablink.com Semrush global rank: 5.4 M Semrush visits lastest month: 1.56 K
- Host name: omics-docs.am.lilly.com
- IP address: 40.255.173.239
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Mablink Bioscience"
Mablink Bioscience - Crunchbase Company Profile
Organization. Mablink Bioscience . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. …See details»
Mablink 2025 Company Profile: Valuation, Investors, Acquisition
Mablink General Information Description. Operator of a biotechnology company intended to develop antibody-drug-conjugates drugs to fight cancer. The company helps to design …See details»
Mablink Bioscience SAS - Drug pipelines, Patents, Clinical trials
Mar 7, 2025 Explore Mablink Bioscience SAS with its drug pipeline, therapeutic area, technology platform, 18 news, Disease Domain:Neoplasms, Hemic and Lymphatic Diseases, Immune …See details»
Mablink Bioscience Company Profile - Office Locations ... - Craft
Mablink Bioscience has 5 employees across 2 locations and $4.84 m in total funding,. See insights on Mablink Bioscience including office locations, competitors, revenue, financials, …See details»
Mablink Bioscience - Funding, Financials, Valuation & Investors
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Oct 14, 2022: Series A - …See details»
Mablink Bioscience - Merieux Partners
Mablink Bioscience The company is developing an innovative chemical masking platform for the optimization of antibody conjugate drug candidates (ADCs) for the treatment of cancer. The …See details»
Mablink Bioscience - Leadership Team - The Org
The Leadership Team at Mablink Bioscience is responsible for setting the strategic direction and vision of the company. They oversee the development and commercialization of innovative …See details»
Mablink Bioscience - Contacts, Employees, Board Members
Mablink Bioscience is a biotechnology company. New. Resources. Advanced Search. Start Free Trial ... Experience the new Crunchbase, powered by AI . Experience the new Crunchbase, …See details»
Mablink - 2025 Company Profile, Funding & Competitors - Tracxn
Mar 5, 2025 Mablink - Provider of Antibody-Drug-Conjugates (ADC's) technology for cancer treatment. Acquired by Lilly. Raised a total funding of $35M over 3 rounds from 11 investors. …See details»
Mablink Bioscience SAS - life-sciences-europe.com
Mablink Bioscience is a French-based biopharmaceutical company which has developed PSARlink™, an innovative and patented hydrophilic drug-linker technology that brings …See details»
Lilly makes another ADC play, buying Mablink - pharmaphorum
1 day ago In a statement, Mablink’s chief executive, Jean-Guillaume Lafay (pictured top), said Lilly’s offer is “a strong endorsement of our approach, our technology, and our team.” The …See details»
Mablink Bioscience Enters an Agreement to be Acquired by
Oct 18, 2023 For more information, please visit https://mablink.com. Press Contacts: Lilly: Lauren Cohen 617.678.2067. lcohen@loxooncology.com. Attachment. Mablink Bioscience …See details»
Mablink Bioscience, the next generation ADC company, raises
Apr 27, 2021 Mablink Bioscience's platform presents a best-in-class approach and has the potential to deliver the next wave of innovation to the promising field of antibody drug …See details»
Mablink Bioscience Enters an Agreement to be Acquired by Lilly
Jean-Guillaume Lafay, Mablink’s Chief Executive Officer, stated: “Mablink’s agreement to be acquired by Lilly is a strong endorsement of our approach, our technology and our team. ...See details»
Mablink Bioscience Company Information - Funding, Investors
The company Mablink Bioscience has raised a total of $34.92m in funding over 2 rounds. Key Insights: Series A: $30.14m; Seed: $4.78m; 2021. Mablink Bioscience Seed (2021, $4M) …See details»
Mablink Bioscience enters an agreement to be acquired by Lilly
Lyon, France – October 18, 2023 - Mablink Bioscience (“Mablink”), a pre-clinical biotechnology company pioneering the development of next-generation antibody-drug conjugates (ADCs) via …See details»
Mablink Bioscience Enters an Agreement to be Acquired by Lilly
Oct 18, 2023 The pending acquisition reflects the potential of Mablink’s existing pipeline and proprietary PSARLink™ technology for development of additional drug conjugates. Lyon, …See details»
Eli Lilly expands ADC scope with Mablink Bioscience acquisition
Oct 19, 2023 In March 2023, Mablink revealed preclinical data for its lead ADC candidate MBK-103 at the American Association for Cancer Research (AACR) meeting, announcing plans to …See details»
Mablink Bioscience Enters an Agreement to be Acquired by Lilly
Oct 18, 2023 Jean-Guillaume Lafay, Mablink’s Chief Executive Officer, stated: “Mablink’s agreement to be acquired by Lilly is a strong endorsement of our approach, our technology …See details»
Mablink Bioscience, the next generation ADC company, raises €4 …
LYON, France, April 27, 2021 /PRNewswire/ -- Mablink Bioscience, a company developing the next generation of antibody-drug conjugates (ADC) through its proprietary hydrophilic drug …See details»